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Abstract
Methylmalonic acid (MMA), a functional indicator of vitamin B12 insufficiency, was measured in 
the U.S. population in the National Health and Nutrition Examination Survey (NHANES) from 
1999–2004 using a GC/MS procedure that required 275 µL of sample and had a low throughput 
(36 samples/run). Our objective was to introduce a more efficient, yet highly accurate LC-MS/MS 
method for NHANES 2011–2014. We adapted the sample preparation with some modifications 
from a published isotope-dilution LC-MS/MS procedure. The procedure utilized liquid-liquid 
extraction and generation of MMA di-butyl ester. Reversed-phase chromatography with isocratic 
elution allowed baseline resolution of MMA from its naturally occurring structural isomer 
succinic acid within 4.5 min. Our new method afforded an increased throughput (≤160 samples/
run) and measured serum MMA with high sensitivity (LOD = 22.1 nmol/L) in only 75 µL of 
sample. Mean (±SD) recovery of MMA spiked into serum (2 days, 4 levels, 2 replicates each) was 
94±5.5%. Total imprecision (41 days, 2 replicates each) for three serum quality control pools was 
4.9–7.9% (97.1–548 nmol/L). The LC-MS/MS method showed excellent correlation (n=326, 
r=0.99) and no bias (Deming regression, Bland-Altman analysis) compared to the previous 
GC/MS method. Both methods produced virtually identical mean (±SD) MMA concentrations 
[LC-MS/MS: 18.47±0.71 ng/mL (n=17), GC/MS: 18.18±0.67 ng/mL (n=11)] on a future plasma 
reference material compared to a GC/MS method procedure from the National Institute of 
Standards and Technology [18.41±0.70 ng/mL (n=15)]. No adjustment will be necessary to 
compare previous (1999–2004) to future (2011–2014) NHANES MMA data.
1No specific sources of financial support. The findings and conclusions in this report are those of the authors and do not necessarily 
represent the official views or positions of the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease 
Registry. Certain commercial equipment, instruments, or materials are identified in this paper to specify adequately the experimental 
procedure. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, 
nor does it imply that the materials or equipment identified are necessarily the best available for the purpose.
*Corresponding Author: Christine M. Pfeiffer. Division of Laboratory Sciences, National Center for Environmental Health, Centers 
for Disease Control and Prevention. 4770 Buford Hwy, NE, Mail Stop F55, Atlanta, GA 30341. CPfeiffer@cdc.gov. Phone: 
770-488-7926. Fax: 770-488-4139. 
HHS Public Access
Author manuscript
Anal Bioanal Chem. Author manuscript; available in PMC 2016 April 01.
Published in final edited form as:














MMA; method comparison; GC/MS; anticoagulant types; NHANES; NIST SRM 1950; vitamin 
B12
Introduction
Cobalamin (vitamin B12) is an essential cofactor for 2 enzymes involved in one-carbon 
metabolism: methylmalonyl CoA mutase and methionine synthetase [1]. Reduced function 
of the former enzyme results in increased serum methylmalonic acid (MMA) concentrations. 
Untreated vitamin B12 deficiency leads to megaloblastic anemia and/or irreversible central 
nervous system degeneration [2]. Serum or plasma vitamin B12 concentrations, particularly 
in the low-normal range, may not adequately reflect tissue vitamin B12 status [3]. Increased 
MMA concentrations are specific for and believed to be the first indication of vitamin B12 
deficiency [4]. MMA in serum or plasma was therefore found to be a useful indicator of 
vitamin B12 deficiency, especially in patients with few or no hematological abnormalities, 
normal results for the Schilling test, or normal or only slightly depressed serum vitamin B12 
concentrations [5].
Various analytical methods for the measurement of MMA in biological fluids have been 
reported, mainly since the 1980s. Different approaches were taken for sample preparation 
(e.g., ultrafiltration, solid-phase or liquid-liquid extraction) and analytical measurement 
(e.g., GC/MS, electrophoresis, and more recently LC-MS/MS) [6–19]. The analysis of 
serum MMA presents several challenges: this dicarboxylic acid has a small molecular 
weight, is hydrophilic, non-volatile, and its concentration in serum is relatively low, 
especially in the generally healthy population with a low prevalence of vitamin B12 
deficiency. This makes direct analysis by GC/MS challenging and various types of 
derivatization (silylation, cyclohexanol, chloroformate and butanol) have been reported to 
improve detection [6–9]. LC-MS/MS methods [10–18], yield shorter run times and better 
sensitivity compared to GC/MS procedures. These two factors are critical when a method is 
used for population monitoring because they translate to higher throughput and lower patient 
sample volume.
The NHANES has measured plasma MMA concentrations in the U.S. population from 
1999–2004 using a GC/MS procedure that required 275 µL of sample and had a low 
throughput (36 samples/run) [19]. No MMA data are available for 2005–2010. A 2010 
expert roundtable discussing “NHANES Monitoring of Biomarkers of Folate and Vitamin 
B-12 Status” recommended that serum MMA measurements be reinstated in future 
NHANES in conjunction with serum vitamin B12 measurements [20]. Our primary objective 
was to introduce a more efficient, yet highly accurate LC-MS/MS method for NHANES 
2011–2014. Our secondary objective was to compare this new method to the previously 
used GC/MS procedure in order to provide continuity in interpreting NHANES data. Lastly, 
we aimed to assess how these two procedures compare to the GC/MS measurement 
procedure used by the National Institute of Standards and Technology (NIST).
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Chemicals, reagents, and samples
MMA, succinic acid, tert-butyl methyl ether (MTBE) and 3 M hydrochloric acid in n-
butanol were purchased from Sigma-Aldrich (St. Louis, MO). Deuterium-labeled MMA (d3-
MMA) was purchased from CDN Isotopes (Quebec, Canada). ACS grade methanol, 
phosphoric acid (H3PO4), glacial acetic acid and acetonitrile were purchased from Thermo 
Fisher Scientific (Pittsburgh, PA). Purified water (18 MΩ) was obtained from an Aqua 
Solutions water purification system (Aqua Solutions, Inc., Falmouth, ME) and was used to 
prepare all samples, calibrators and reagents. Quality control (QC) pools (low, medium and 
high) were prepared in-house from pooled human serum purchased from a U.S. blood bank. 
All units were screened for MMA and spiked with MMA standard solution as needed to 
achieve desired concentrations. All specimens were stored at −70 °C when not in use.
Sample preparation and analysis by LC-MS/MS
Samples were prepared by a modified procedure reported by Pedersen et al. [16]. Master 
stock solutions of MMA and d3-MMA were prepared in water (50 µmol/L). Six individual 
MMA working calibrators were prepared from the stock solution in water (25–2500 nmol/L) 
and stored (as 400 µL aliquots) at −70 °C until analysis. We prepared a fresh working 
internal standard (ISTD) solution (1 µmol/L) from the d3-MMA stock solution on the day of 
analysis in 50% methanol/water. The sample preparation steps involved liquid-liquid 
extraction and generation of MMA di-butyl ester (Fig. 1). MMA was separated from 
succinic acid and from other compounds on an Accela UHPLC system (Thermo Fisher 
Scientific, Waltham, MA) by isocratic elution (0.1% acetic acid:methanol 40:60; 0.4 mL/
min) within 4.5 min on a Hypersil Gold C18 analytical column (2.1 mm × 50 mm, 1.9 µm 
particle size) (Thermo Fisher Scientific) held at 35 °C. The total run time was 6 min. 
Samples were maintained at 7 °C within the instrument during the run. Injection volume was 
3 µL in a partial loop mode. Mass detection was carried out on a TSQ Vantage (Thermo 
Fisher Scientific, Waltham, MA) under multiple-reaction monitoring (MRM) conditions in 
positive electrospray ionization (ESI) mode. The mass spectrometer parameters were as 
follows: spray voltage 4500 V, vaporizer temperature 350 °C, nitrogen sheath gas pressure 
30 arbitrary units, auxiliary gas flow 5 arbitrary units, ion transfer capillary temperature 290 
°C, argon collision gas pressure 1.2 mTorr, scan time 200 ms, scan width 0.1 Da, mass 
resolution in Q1 and Q3 0.7 full width at half maximum. We monitored two transitions each 
for MMA (m/z 231 → 119 and 175.1) and for d3-MMA (m/z 234.1 → 122.1 and 178.1) and 
used the sum of the two signals for quantitation, MRM mode. We also used the two 
individual transitions in selected reaction monitoring (SRM) mode to calculate confirmation 
ion ratios. In this calculation, the more abundant transition (m/z 231 →119) was the 
quantitation ion (QISRM), while the less abundant transition (m/z 231 →175.1) was the 
confirmation ion (CISRM). We established confirmation ion ratio (CISRM/QISRM) limits 
(mean ± 2 SD) for MMA from repeated analysis of the calibrators (n = 20). Quantitation 
was based on peak area ratios [analyte/internal standard (ISTD)] interpolated against a six-
point aqueous calibration curve (1/× weighting), using XCalibur software (Thermo Fisher 
Scientific, Waltham, MA). We reinjected the calibrators at the end of each run to assess 
drifting. Each run consisted of a reagent blank (no ISTD), a blank (with ISTD), a set of 
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calibrators, three serum QC samples prepared in duplicate (bracketing the unknown 
samples) and 1 blind QC sample for every 20 unknown samples (see Electronic 
Supplementary Material Fig. S1).
Method validation
We used the FDA “Bioanalytical Method Validation” and IUPAC validation guidelines [21, 
22] as well as our internal division document “Policies and Procedures Manual for 
Bioanalytical Measurements” to design our method validation experiments. We evaluated 
calibrator accuracy for 10 runs by calculating the proportion of measured to nominal 
calibrator value. We assessed the effect of the presence of matrix on the calibration curve 
from a 10-point calibration curve (0–2500 nmol/L, 3 independent calibration curves) 
prepared both in water and in human serum. Slopes that agreed within ± 5% were 
considered to be equivalent. We determined method imprecision using 3 levels of serum QC 
pools: within-run, 10 replicates/level in one run; total and between-run, 2 replicates/level 
over 10 runs. We assessed method accuracy through spike recovery: a serum pool was 
spiked with MMA at 4 levels (2 runs, 2 replicates/level: 50, 250, 700, and 1000 nmol/L). We 
also measured the unspiked serum pool for endogenous MMA concentration (2 runs, 2 
replicates each). To assess spike recovery, we added the ISTD to the samples and carried 
them through the extraction process. To assess extraction efficiency, we added the ISTD 
after extraction was completed. The spike recovery and the extraction efficiency were 
calculated as the measured concentration difference between the spiked and the unspiked 
sample divided by the nominal concentration of the spike. We estimated the limit of 
detection (LOD) by serially diluting the low QC pool with charcoal stripped serum (Aalto 
Scientific, Carlsbad, CA) and calculating the SD at concentrations of zero (σ0) from the 
extrapolation of repeat measurements (3 runs, 3 replicates/dilution) [23]. We defined the 
LOD as 3σ0.
MMA stability
We exposed 3 serum QC pools (97.1, 247 and 548 nmol/L) to room temperature for 1, 2, 3 
and 7 days to assess short-term MMA stability. The vials were returned to −70 °C storage 
and later all samples were processed and analyzed together with pristine serum QC pools 
kept at −70 °C as a reference. We also subjected the same QC pools to repeated freeze-
thawing (up to 3 cycles, 2 hours/cycle at room temperature in closed vials). We studied the 
stability of processed serum extracts for the above set of serum QC pools kept in the 
autosampler compartment at 7 °C for 3 days. In a separate experiment we kept the 96-well 
plate containing processed serum QC pools and 25 unknown samples at −20 °C for 1 week 
and compared the results to the initial results. We assessed mid-term (6 month and 1 year) 
MMA stability using three plasma QC pools (179, 515 and 2007 nmol/L, 3 runs, 1 replicate/
condition) stored at suboptimal temperatures (5 °C and −20 °C). The vials were returned to 
−70 °C storage and later all samples were processed and analyzed together with pristine 
plasma QC pools kept at −70 °C as a reference. Long-term (14 years) MMA stability at ≤ 
−70 °C was assessed from six plasma QC pools (120, 137, 1079, 1825, 10230 and 10295 
nmol/L, 2 runs, 5 replicates/level).
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Effect of specimen type and anticoagulant
To study the effect of different anticoagulants, we used matched serum and plasma samples 
from 14 anonymous blood donors [serum, serum separator, K2EDTA plasma, Na citrate 
plasma and Na heparin plasma (5-mL blood collection tubes with 0.5 mL anticoagulant), 
Tennessee Blood Bank Services (Memphis, TN)]. Plasma was obtained within 2–4 hours of 
blood collection (blood held at room temperature), serum after overnight clotting (leading to 
higher serum yield and less residual fibrinogen clots) at room temperature through 
centrifugation at 4 °C, following standard operating procedures. All specimens were 
refrigerated, shipped on cold packs and frozen at −70 °C within 48 hours of blood 
collection. Serum was used as a reference. Because of the diluent in the plasma citrate tubes, 
we multiplied results for this specimen type by 1.1.
Method comparison studies
We performed three comparison studies to assess how the new LC-MS/MS method 
compared to other methods. First, we subjected randomly selected residual NHANES 
plasma samples (n = 336; MMA: 60–2320 nmol/L) previously analyzed with our GC/MS 
method to analysis by our new LC-MS/MS method. We excluded seven extreme outlier 
results (difference between the two procedures > 40%) and three samples with MMA 
concentrations above 1500 nmol/L to avoid an undue influence of very high concentrations. 
The final set (n = 326; MMA: 60–1180 nmol/L) was evaluated for Pearson correlation, 
Deming regression, and Bland-Altman analysis using Analyse-it, a statistical plug-in for 
Microsoft Excel (Analyse-it version 2.20, Analyse-it Software, LTD, Leeds, U.K.). Second, 
we subjected eight serum and 11 plasma samples (stored at −70 °C for 14 years) from a 
previous international round-robin study [24] to analysis by our new LC-MS/MS method 
and compared the results to the consensus mean of all 13 participating laboratories and to 
the our previous GC/MS results. Third, we characterized the plasma-based NIST Standard 
Reference Material (SRM) 1950 “Metabolites in Human Plasma” by our LC-MS/MS and 
GC/MS procedures (replicate analyses of 6 vials over 3 days). This material was also 
characterized by a NIST GC/MS measurement procedure that has been used in value 
assignment of NIST reference materials. For all three methods we calculated the mean ± SD 
and the coefficient of variation (CV). This evaluation was another accuracy assessment of 
the new LC-MS/MS method.
Results and discussion
The sample preparation procedure (adapted from Pedersen et al. with some minor 
modifications) involved liquid-liquid extraction of MMA from serum, followed by 
derivatization of MMA to dibutyl ester and analysis by positive ion ESI-LC-MS/MS.
We optimized and tested critical sample preparation steps. Because the addition of acid to 
the organic solvent improves the transfer of organic acid from the aqueous to the organic 
phase, we tested extraction efficiency with different concentrations of o-phosphoric acid 
(0.1, 0.25 and 0.5 M) on a set of calibrators and QC samples. We obtained poor MMA 
extraction with 0.1 M o-phosphoric acid in MTBE and selected the 0.5 M acid concentration 
because it provided optimum MMA extraction from the aqueous phase (data not shown). 
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Placing the tubes into a dry ice/ethanol bath was a fast and efficient way to separate the 
organic from the aqueous layer by simply decanting the top (MTBE) layer after the bottom 
(aqueous) layer froze. This process happened very quickly and small variations in the 
amount of time the samples were kept in the ice bath (1, 2, or 3 min) did not influence the 
MMA areas in a set of calibrators and QC samples. Because the derivatization of extracted 
MMA to the dibutyl ester (at 60 °C) is a critical step, we studied the timing on the heating 
block to monitor reaction completion (20, 30, and 40 min). The use of excess of 
derivatization reagent and a 30 min incubation time assured that even samples with high 
MMA concentrations (above 10,000 nmol/L) completed the reaction. The derivatized 
samples have to be subjected to evaporation to remove the excess of the high boiling 
derivatization reagent (3 M HCl in n-butanol). In our experience longer evaporation times, 
involving vacuum and heat, can reduce the recovery of the volatile MMA dibutyl ester 
(optimum evaporation time is 30 min at 45 °C under vacuum, data not shown).
One important challenge in the analysis of serum MMA is the potential interference from 
other low-mass carboxylic acids, especially the structural isomer succinic acid, which is 
present in serum in high concentrations. Because the mass spectra of the two acids are 
nearly identical, MMA and succinic acid have to be separated chromatographically. To 
achieve the best resolution, we tested several reversed phase analytical columns 
(pentafluorophenyl, cyano, and C18). We selected the C18 UHPLC column because it 
allowed excellent resolution between MMA and succinic acid with relatively fast isocratic 
chromatography, narrow analyte peaks and excellent column life (typically ~2000 
injections) (Fig. 2). Our LC-MS/MS method offers an additional degree of specificity 
because it features data collection from two specific MMA transitions (QISRM and CISRM). 
We obtained fairly low (± 8%) variation of the confirmation ion ratio when we monitored 
these two ions in all 6 calibrators over 20 runs, particularly compared to common “industry 
standards” (FDA: ± 10% [25]; Society of Forensic Toxicologists: ± 20% to ± 30% [26]; 
European Commission: ± 20% to ± 50% depending of the abundance of CISRM vs. QISRM 
[27]). When we applied the confirmation ion ratio limits to MMA results > 150 nmol/L 
obtained from 600 serum samples, 99% of samples met the predetermined limits. This 
indicates that our confirmation ion ratio limits, while narrow, can be used in routine 
applications to allow identification of a potentially interfering compound that may be 
present in a sample.
Our previous GC/MS procedure [19], while performing reliably for the measurement of 
thousands of NHANES samples, was not an efficient method. The sample volume 
requirement was 275 µL/test, the GC/MS run time was 15 min, the throughput was limited 
to 36 samples/run, and the sample preparation time for one run was ~12 hours (Table 1). 
With the new LC-MS/MS method we achieved our main goal to improve the method 
efficiency. The LC-MS/MS method used a much reduced sample volume (75 µL), allowed a 
notably faster sample preparation time (~4 hours) and LC-MS/MS run time (6 min), and had 
a much higher sample throughput (up to 160 unknown samples/run).
We subjected our LC-MS/MS method to complete method validation. Ion suppression was 
evaluated by post-column infusion (using a T-connection) of 50 nmol/L MMA-dibutyl 
solution while injecting a reagent blank, a blank, standards, unknown and QC samples. No 
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baseline drifts were observed around the elution time of MMA upon injection of matrix and 
non-matrix samples indicating lack of ion suppression. We verified and confirmed that 
aqueous calibration produced an equivalent slope (0.0025, r2 = 0.999) compared to 
calibration in serum (0.0024, r2 = 0.994). The average slopes differed by 4.1%. Due to 
matrix equivalency, we prepared many aliquots of aqueous calibrators, stored them at −70 
°C, and used a new set with each run, which greatly simplified method implementation and 
daily routine preparations for the analyst. The aqueous calibration curve showed linearity 
over two orders of magnitude (25–2500 nmol/L) with a high correlation coefficient (r2 = 
0.999). Some investigators reported storage at −20 °C as preferred over storage at −80 °C 
(for aqueous calibrators [16] or for serum-based calibrators [12]) due to possible MMA 
absorption to the storage container surface. We have not observed any change in method 
performance with aqueous calibrators stored in 2-mL Nalgene vials for up to 2 years at −80 
°C (data not shown).
Our LC-MS/MS method achieved good precision with a total CV of 4.9–7.9% for three 
serum QC pools analyzed over 22 runs (Table 2), similar to the precision of the GC/MS 
method (CV of 5.4 % for three plasma QC pools analyzed over 56 runs, [19]) and to other 
LC-MS/MS methods [10–18]. We can rate our method precision more objectively by using 
generally applicable quality goals based on biologic variation [28]. As such, the analytical 
variation CVa should be a fraction of the within-person biologic variation CVw; optimum 
performance, CVa = 0.25 × CVw, desirable performance, CVa = 0.5 × CVw, minimum 
performance, CVa = 0.75 × CVw. Lacher et al. reported a within-person biologic variation of 
18.7% for MMA using data from NHANES 1999–2002 [29]. Therefore, the optimum, 
desirable, and minimum precision performance criteria for MMA are < 4.7%, < 9.4%, and < 
14%, respectively. Our LC-MS/MS method achieved desirable precision.
We evaluated method accuracy through spike recovery. The use of an isotopically-labeled 
ISTD is expected to correct for any loss of analyte during sample handling. The high 
accuracy assessed through spike recovery for the LC-MS/MS method (94% ± 5.5%) was 
comparable to that reported for the GC/MS method (96% ± 1.9%, [19]) and to other LC-
MS/MS methods [10–18]. Our LC-MS/MS method also achieved a good extraction 
efficiency of 81%, as assessed from post-extraction addition of ISTD.
The LC-MS/MS method sensitivity, as expressed by the LOD (22.1 nmol/L), was improved 
compared to our previous GC/MS method (50 nmol/L) and commensurate or better 
compared to other LC-MS/MS methods [11, 13, 14, 15]. The use of MRM in our LC-
MS/MS method allowed us to monitor a cumulative signal for quantitation (sum of 
quantitation and confirmation ion areas). This produced a notable increase in signal, while 
keeping the background approximately the same. The confirmation ion area contributed 
~60–85% of the quantitation ion area. Thus, MRM helped to improve our method detection 
limit. The improved sensitivity of our new LC-MS/MS method and the small sample volume 
requirement (75 µL) allowed the accurate measurement of MMA at normal concentrations 
encountered in population surveys. Low-volume samples (<100 µL) that require 
confirmation can be diluted with deionized water and reanalyzed.
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Plasma can form micro-fibrinogen clots during long-term storage, therefore serum is 
generally preferred. After we adjusted for the dilution in the plasma citrate tube, we found 
interchangeable results among the matched serum (plain and serum separators tubes) and 
plasma (EDTA, Na heparin, and citrate) samples (n = 14) with a mean difference of ± 3% 
(Fig. 3). This was generally consistent with other reports [11, 18], however Kushnir et al. 
reported an interference with the citrate tube, causing a significant increase of the 
confirmation ion ratio [11].
We assessed the short-term stability of MMA in serum and in extracted samples, mid- and 
long-term stability of MMA in refrigerated and/or frozen serum, and the stability of MMA 
during repeated freeze/thawing of serum, and the short-term stability of MMA in extracted 
samples. We confirmed previous reports [16, 18] that MMA was stable for up to three 
freeze/thawing cycles and for up to one week of serum storage at room temperature (data not 
shown). Given these results, it was not surprising that the short-term stability of MMA in 
extracted samples (3 days at 7 °C and 1 week at −20 °C) was also very good (± 3 % and ± 
1%, respectively from the original value). Furthermore, storage of serum at −20 °C for one 
year also showed excellent stability with no significant change in MMA concentrations from 
baseline [mean percent difference (95% CI) among the three serum QC pools: 0.98% 
(−1.46% to −3.47%), P = 0.42]. Storage of serum at 5 °C for one year showed a small but 
significant increase in MMA [6.59% (2.19% to 11.2%), P = 0.0048], possibly due to slight 
sample evaporation. However, the 6 month time point for storage at 5 °C showed no 
significant changes. This excellent MMA stability makes it possible to ship serum at 
ambient temperature to laboratories around the world participating in external quality 
assessment schemes. Lastly, the long-term (up to 14 years) stability of frozen (≤ −70 °C) 
plasma QC pools that were originally value assigned by our GC/MS method was also 
excellent with MMA concentrations being within ± 1% of the original target values.
The second objective of this report was to compare our new LC-MS/MS method to the 
previous GC/MS method as to provide continuity in interpreting NHANES data. The mean 
± SD (nmol/L) MMA concentration in the final set of 326 residual NHANES samples was 
236 ± 191 nmol/L by LC-MS/MS compared to 235 ± 186 nmol/L by GC/MS. The two 
methods showed excellent correlation (Pearson r = 0.99). Deming regression analysis 
showed a significant but small deviation from a slope of 1 and an intercept of 0 and a non-
significant bias (Table 3 and Fig. 4). Therefore no adjustments will be needed to compare 
the NHANES 1999–2004 GC/MS data to the new NHANES 2011–2014 LC-MS/MS data. 
Using a much smaller sample set from a previously conducted international round-robin (n = 
19, concentration range: 70–10500 nmol/L, [24]), we also found excellent correlation 
(Pearson r = 1.0) and no bias between our LC-MS/MS method and the earlier generated 
GC/MS or consensus results from 13 laboratories (Table 3).
At present, there is no serum-based reference material available with certified MMA 
concentrations. As an additional accuracy evaluation of the new LC-MS/MS method and as 
part of our third objective, we compared our results by both the LC-MS/MS and the GC/MS 
method to those obtained by NIST on a future NIST SRM material. SRM 1950 “Metabolites 
in Human Plasma” is the first reference material that has been characterized for MMA by 
the NIST GC/MS and CDC GC/MS and LC-MS/MS measurement procedures. The mean ± 
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SD (ng/mL) MMA concentrations obtained by the three procedures were virtually identical: 
CDC LC-MS/MS, 18.47 ± 0.71 (n = 17); CDC GC/MS, 18.18 ± 0.67 (n = 11); NIST 
GC/MS, 18.41 ± 0.70 (n = 15). The variability (CV) of the three procedures was also very 
comparable: 3.8%, 3.7%, and 3.8%, respectively.
In summary, with this new LC-MS/MS method we have implemented important features for 
methods used in large population surveys: low sample volume and high throughput, high 
accuracy, low imprecision and good sensitivity. Time will show how stable the method will 
perform long-term. However, so far an intermittent use of the method did not pose any 
problems in bringing the method back online after several months of pausing. The excellent 
comparability and bias-free agreement between this method and the NIST GC/MS 
measurement procedure as well as our previous GC/MS method will facilitate future time 
trend analyses using NHANES data.
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Sample preparation steps for MMA LC-MS/MS method
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Typical chromatogram of the low quality control serum
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Effect of specimen type and anticoagulant on MMA. Fourteen matched serum and plasma 
samples were analyzed with the LC-MS/MS method. Error bars represent standard error. 
Because Na citrate was a liquid (0.5 mL/5 mL vacutainer tube) anticoagulant, MMA results 
were multiplied by 1.1 to correct for the dilution.
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Comparison of LC-MS/MS to GC/MS results obtained for MMA. Method comparison 
consisted of 326 residual plasma samples. Deming regression (Panel A). Bland-Altman plot 
of differences (Panel B).
Mineva et al. Page 14

























Mineva et al. Page 15
Table 1
Sample preparation and analysis steps, comparing the CDC LC-MS/MS and GC/MS methods for MMA.
Step LC-MS/MS GC/MS
Sample volume/test, µL 75 275
Calibration range, nmol/L 25–2500 0–20000
Number of calibrators 6 1
Specimen type Serum Plasma
Derivative analyzed Dibutyl ester Dicyclohexyl ester
Derivative used for analysis, (amount, µL) 3M HCl in BuOH (125) 1.5 M HCl in cyclohexanol (200)
Derivatization time/temperature, min/°C 30/60 15/115
Sample extraction technique Liquid-liquid extraction Solid-phase extraction
Sample preparation time, h 4 12
Injection volume, µL 3 1
Throughput (samples/run) 160 36
Chromatographic run time, min 6 15
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Table 3
Comparison of MMA results in serum and plasma samples obtained by different methods.









LC-MS/MS vs. GC/MSa 0.99 (0.99 to 1.0) 1.03 (1.00 to 1.06) −6.34 (−12.4 to 0.32) 0.92 (−1.42 to 3.26)
LC-MS/MS vs. GC/MSb 1.0 (1.0 to 1.0) 1.03 (0.94 to 1.10) 13.3 (−6.92 to 33.5) −22.5 (−84.3 to 39.3)
LC-MS/MS vs. consensusb 1.0 (1.0 to 1.0) 0.99 (0.93 to 1.05) −10.8 (−24.0 to 2.44) −75.9 (−148.8 to −2.9)
a
Plasma samples (n = 326) were used for analysis
b
Eight serum and 11 plasma samples were used for analysis
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